{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:26:31Z","timestamp":1793139991213,"version":"4.5.0"},"reference-count":172,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.phrs.2025.108077","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:00:06Z","timestamp":1767114006000},"page":"108077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes"],"prefix":"10.1016","volume":"223","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1178-1936","authenticated-orcid":false,"given":"Andrew J.","family":"Elmendorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1626-0522","authenticated-orcid":false,"given":"Mostafa","family":"Yousefian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-8337","authenticated-orcid":false,"given":"Il-Man","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Andrew","family":"Hardaway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-5480","authenticated-orcid":false,"given":"Kirk","family":"Habegger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3433-4602","authenticated-orcid":false,"given":"Jonathan N.","family":"Flak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.108077_bib1","series-title":"IDF Diabetes Atlas","author":"Magliano","year":"2021"},{"key":"10.1016\/j.phrs.2025.108077_bib2","series-title":"World Obesity Atlas 2023","author":"Tim Lobstein","year":"2023"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker","year":"2024","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/09581596.2024.2333407","article-title":"The economic burden of obesity in 2024: a cost analysis using the value of a statistical life","volume":"34","author":"Sweis","year":"2024","journal-title":"Crit. Public Health"},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12061320","article-title":"New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes-Beyond and within GLP-1 Receptor Agonists","volume":"12","author":"Sztanek","year":"2024","journal-title":"Biomedicines"},{"key":"10.1016\/j.phrs.2025.108077_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1530985","article-title":"The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP","volume":"16","author":"Douros","year":"2025","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib7","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s13300-024-01566-x","article-title":"Dual and triple incretin-based co-agonists: novel therapeutics for obesity and diabetes","volume":"15","author":"Gutgesell","year":"2024","journal-title":"Diabetes Ther."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00125-013-2841-0","article-title":"Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies","volume":"56","author":"Calanna","year":"2013","journal-title":"Diabetologia"},{"key":"10.1016\/j.phrs.2025.108077_bib9","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.diabres.2018.05.034","article-title":"The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis","volume":"142","author":"Maciel","year":"2018","journal-title":"Diabetes Res Clin. Pr."},{"key":"10.1016\/j.phrs.2025.108077_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.868037","article-title":"Is Glucagon receptor activation the thermogenic solution for treating obesity?","volume":"13","author":"Conceicao-Furber","year":"2022","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib11","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S2213-8587(22)00349-7","article-title":"Glucagon, from past to present: a century of intensive research and controversies","volume":"11","author":"Scheen","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.phrs.2025.108077_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"key":"10.1016\/j.phrs.2025.108077_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.110696","article-title":"Direct effects of glucagon on glucose uptake and lipolysis in human adipocytes","volume":"503","author":"Pereira","year":"2020","journal-title":"Mol. Cell Endocrinol."},{"issue":"21","key":"10.1016\/j.phrs.2025.108077_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20215407","article-title":"Glucagon regulation of energy expenditure","volume":"20","author":"Kleinert","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib15","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1210\/jc.2015-2335","article-title":"Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 infusion on food intake, appetite, and resting energy expenditure","volume":"100","author":"Bagger","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib16","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1172\/JCI107537","article-title":"Effects of glucagon on lipolysis and ketogenesis in normal and diabetic men","volume":"53","author":"Liljenquist","year":"1974","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.108077_bib17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJM196105042641801","article-title":"Depression of food intake induced in healthy subjects by glucagon","volume":"264","author":"Penick","year":"1961","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1042\/bj0010028","article-title":"On the treatment of diabetus mellitus by acid extract of duodenal mucous membrane","volume":"1","author":"Moore","year":"1906","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF00220741","article-title":"Types of endocrine cells in the human colon and rectum","volume":"192","author":"Buffa","year":"1978","journal-title":"Cell Tissue Res."},{"issue":"S1","key":"10.1016\/j.phrs.2025.108077_bib20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/dom.13129","article-title":"Incretin hormones: Their role in health and disease","volume":"20","author":"Nauck","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S2213-8587(15)00482-9","article-title":"The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions","volume":"4","author":"Nauck","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib22","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1210\/jcem-24-10-1076","article-title":"Insulin Response to Oral and Intravenous Glucose Administration1. The","volume":"24","author":"ELRICK","year":"1964","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib23","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1172\/JCI105685","article-title":"Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects","volume":"46","author":"Perley","year":"1967","journal-title":"J. Clin. Investig."},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib24","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1530\/eje.0.1460863","article-title":"The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects","volume":"146","author":"Hui","year":"2002","journal-title":"Eur. J. Endocrinol."},{"issue":"3 Pt 1","key":"10.1016\/j.phrs.2025.108077_bib25","first-page":"E458","article-title":"Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig","volume":"271","author":"Deacon","year":"1996","journal-title":"Am. J. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib26","doi-asserted-by":"crossref","first-page":"654","DOI":"10.2337\/diabetes.53.3.654","article-title":"Secretion, Degradation, and Elimination of Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide in Patients with Chronic Renal Insufficiency and Healthy Control Subjects","volume":"53","author":"Meier","year":"2004","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib27","first-page":"952","article-title":"Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo","volume":"80","author":"Deacon","year":"1995","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib28","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1210\/endo.136.8.7628397","article-title":"Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV","volume":"136","author":"Kieffer","year":"1995","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib29","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/j.1432-1033.1993.tb17986.x","article-title":"Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7\u201336)amide, peptide histidine methionine and is responsible for their degradation in human serum","volume":"214","author":"MENTLEIN","year":"1993","journal-title":"Eur. J. Biochem."},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib30","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2337\/dc07-0228","article-title":"Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes: Preclinical biology and mechanisms of action","volume":"30","author":"Drucker","year":"2007","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib31","doi-asserted-by":"crossref","first-page":"7402","DOI":"10.1016\/S0021-9258(18)42531-8","article-title":"Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas","volume":"267","author":"Eng","year":"1992","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib32","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2165\/00003495-200565120-00008","article-title":"Exenatide","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib33","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2165\/00003495-200767060-00008","article-title":"Exenatide","volume":"67","author":"Cvetkovi\u0107","year":"2007","journal-title":"Drugs"},{"issue":"24","key":"10.1016\/j.phrs.2025.108077_bib34","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1021\/jm070861j","article-title":"Structure\u2212activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives:\u2009importance of fatty acid length, polarity, and bulkiness","volume":"50","author":"Madsen","year":"2007","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.phrs.2025.108077_bib35","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1001\/jama.2023.19897","article-title":"Obesity management in adults: a review","volume":"330","author":"Elmaleh-Sachs","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.phrs.2025.108077_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.12.032","article-title":"A review of lipidation in the development of advanced protein and peptide therapeutics","volume":"295","author":"Menacho-Melgar","year":"2019","journal-title":"J. Control Release"},{"issue":"18","key":"10.1016\/j.phrs.2025.108077_bib37","doi-asserted-by":"crossref","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","article-title":"Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide","volume":"58","author":"Lau","year":"2015","journal-title":"J. Med Chem."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide Once Weekly for the Treatment of Obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"10160","key":"10.1016\/j.phrs.2025.108077_bib39","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/S0140-6736(18)32260-8","article-title":"Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial","volume":"392","author":"Frias","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.108077_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116893","article-title":"Development of a long-acting unbiased GIP receptor agonist for studies of GIP's role in bone metabolism","volume":"236","author":"Tordrup","year":"2025","journal-title":"Biochem Pharm."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib41","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s42255-023-00966-w","article-title":"A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings","volume":"6","author":"V\u00e9niant","year":"2024","journal-title":"Nat. Metab."},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib42","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.tem.2024.04.016","article-title":"Antagonizing GIPR adds fire to the GLP-1R flame","volume":"35","author":"Novikoff","year":"2024","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib43","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1002\/oby.23095","article-title":"Physiology of Energy Expenditure in the Weight-Reduced State","volume":"29","author":"Ravussin","year":"2021","journal-title":"Obes. (Silver Spring)"},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib44","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","article-title":"Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation","volume":"37","author":"Ravussin","year":"2025","journal-title":"Cell Metab."},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1002\/oby.21538","article-title":"Persistent metabolic adaptation 6 years after \"The Biggest Loser\" competition","volume":"24","author":"Fothergill","year":"2016","journal-title":"Obes. (Silver Spring)"},{"key":"10.1016\/j.phrs.2025.108077_bib46","article-title":"A Mechanistic Rationale for Incretin-Based Therapeutics in the Management of Obesity","author":"Samms","year":"2024","journal-title":"Annu Rev. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib47","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3803\/EnM.2016.31.3.361","article-title":"Novel Molecules Regulating Energy Homeostasis: Physiology and Regulation by Macronutrient Intake and Weight Loss","volume":"31","author":"Gavrieli","year":"2016","journal-title":"Endocrinol. Metab. (Seoul. )"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib48","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2337\/diab.47.1.93","article-title":"Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats","volume":"47","author":"Gedulin","year":"1998","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib49","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm.3761","article-title":"A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents","volume":"21","author":"Finan","year":"2015","journal-title":"Nat. Med"},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib50","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib51","doi-asserted-by":"crossref","first-page":"E671","DOI":"10.1152\/ajpendo.00492.2002","article-title":"Glucagon and regulation of glucose metabolism","volume":"284","author":"Jiang","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2337\/diab.6.3.248","article-title":"The pathologic effects of large amounts of glucagon","volume":"6","author":"Salter","year":"1957","journal-title":"Diabetes"},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib53","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib54","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.2337\/db09-0278","article-title":"Glucagon-Like Peptide 1\/Glucagon Receptor Dual Agonism Reverses Obesity in Mice","volume":"58","author":"Pocai","year":"2009","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib55","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1177\/193229681000400605","article-title":"Optimization of the native glucagon sequence for medicinal purposes","volume":"4","author":"Chabenne","year":"2010","journal-title":"J. Diabetes Sci. Technol."},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib56","doi-asserted-by":"crossref","first-page":"3340","DOI":"10.1073\/pnas.74.8.3340","article-title":"Thermodynamics of the self-association of glucagon","volume":"74","author":"Formisano","year":"1977","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib57","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1432-1033.1972.tb02558.x","article-title":"Presence of Trimers in Glucagon Solution","volume":"31","author":"Gratzer","year":"1972","journal-title":"Eur. J. Biochem."},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib58","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1023\/B:PHAM.0000033016.36825.2c","article-title":"Mishandling of the Therapeutic Peptide Glucagon Generates Cytotoxic Amyloidogenic Fibrils","volume":"21","author":"Onoue","year":"2004","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib59","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon receptor signaling regulates energy metabolism via hepatic farnesoid x receptor and fibroblast growth factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3390\/ph14050435","article-title":"Targeting energy expenditure\u2014drugs for obesity treatment","volume":"14","author":"Jimenez-Munoz","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib61","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/nrendo.2017.122","article-title":"Current pharmacotherapy for obesity","volume":"14","author":"Srivastava","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib62","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.2337\/db14-0242","article-title":"Coinfusion of Low-Dose GLP-1 and Glucagon in Man Results in a Reduction in Food Intake","volume":"63","author":"Cegla","year":"2014","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib63","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes. Metab."},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib64","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/dom.14948","article-title":"Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor\/glucagon-like peptide-1 receptor agonist BI 456906","volume":"25","author":"Jungnik","year":"2023","journal-title":"Diabetes Obes. Metab."},{"issue":"22","key":"10.1016\/j.phrs.2025.108077_bib65","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight","volume":"392","author":"Ji","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib66","article-title":"Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors","volume":"13","author":"Zhao","year":"2022","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib67","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib68","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.cmet.2022.07.013","article-title":"LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept","volume":"34","author":"Coskun","year":"2022","journal-title":"Cell Metab."},{"issue":"10366","key":"10.1016\/j.phrs.2025.108077_bib69","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib70","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Retatrutide Phase 2 Obesity Trial I. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2025.108077_bib71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"Muller","year":"2019","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib72","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1074\/jbc.M114.592436","article-title":"Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking","volume":"290","author":"Roed","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib73","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0303-7207(94)90162-7","article-title":"Relative quantitative analysis of glucagon receptor mRNA in rat tissues","volume":"105","author":"Svoboda","year":"1994","journal-title":"Mol. Cell Endocrinol."},{"issue":"13","key":"10.1016\/j.phrs.2025.108077_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20133314","article-title":"Glucagon Receptor Signaling and Glucagon Resistance","volume":"20","author":"Janah","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib75","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1073\/pnas.73.8.2762","article-title":"Hormonal control of pyruvate kinase activity and of gluconeogenesis in isolated hepatocytes","volume":"73","author":"Feliu","year":"1976","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108077_bib76","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.mce.2013.05.021","article-title":"Hepatic ERK activity plays a role in energy metabolism","volume":"375","author":"Jiao","year":"2013","journal-title":"Mol. Cell Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib77","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1210\/me.2004-0194","article-title":"The role of uncoupling protein 1 in the metabolism and adiposity of RII beta-protein kinase A-deficient mice","volume":"18","author":"Nolan","year":"2004","journal-title":"Mol. Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib78","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1073\/pnas.83.9.2797","article-title":"Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor","volume":"83","author":"Benovic","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5402","key":"10.1016\/j.phrs.2025.108077_bib79","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1126\/science.283.5402.655","article-title":"Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes","volume":"283","author":"Luttrell","year":"1999","journal-title":"Science"},{"issue":"51","key":"10.1016\/j.phrs.2025.108077_bib80","doi-asserted-by":"crossref","first-page":"51334","DOI":"10.1074\/jbc.M309968200","article-title":"Beta-arrestin1 mediates insulin-like growth factor 1 (IGF-1) activation of phosphatidylinositol 3-kinase (PI3K) and anti-apoptosis","volume":"278","author":"Povsic","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.108077_bib81","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016334","article-title":"Genetic and biased agonist-mediated reductions in \u03b2-arrestin recruitment prolong cAMP signaling at glucagon family receptors","volume":"296","author":"Jones","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.108077_bib82","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0196-9781(86)90166-X","article-title":"Superactive amidated COOH-terminal glucagon analogues with no methionine or tryptophan","volume":"7","author":"Murphy","year":"1986","journal-title":"Peptides"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib83","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0167-0115(88)90096-1","article-title":"Receptor occupancy and adenylate cyclase activation in rat liver and heart membranes by 10 glucagon analogs modified in position 2, 3, 4, 25, 27 and\/or 29","volume":"21","author":"Robberecht","year":"1988","journal-title":"Regul. Pept."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib84","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0014-5793(97)01556-1","article-title":"Periportal localization of glucagon receptor mRNA in rat liver and regulation of its expression by glucose and oxygen in hepatocyte cultures","volume":"421","author":"Krones","year":"1998","journal-title":"FEBS Lett."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib85","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1172\/JCI106445","article-title":"Glucagon levels and metabolic effects in fasting man","volume":"49","author":"Marliss","year":"1970","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.108077_bib86","first-page":"1240","article-title":"Amatuzio DS, Grande F, Wada S. Effect of glucagon on the serum lipids in essential hyperlipemia and in hypercholesterolemia","volume":"11","year":"1962","journal-title":"Metabolism"},{"key":"10.1016\/j.phrs.2025.108077_bib87","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3389\/fphys.2019.00413","article-title":"Glucagon Receptor Signaling and Lipid Metabolism","volume":"10","author":"Galsgaard","year":"2019","journal-title":"Front Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib88","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1152\/physrev.00028.2023","article-title":"Hepatic glucagon action: beyond glucose mobilization","volume":"104","author":"Kajani","year":"2024","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib89","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.cmet.2008.09.008","article-title":"The glucagon receptor is required for the adaptive metabolic response to fasting","volume":"8","author":"Longuet","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib90","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101080","article-title":"Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis","volume":"42","author":"Winther-Sorensen","year":"2020","journal-title":"Mol. Metab."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib91","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.celrep.2015.06.034","article-title":"Glucagon Couples Hepatic Amino Acid Catabolism to mTOR-Dependent Regulation of alpha-Cell Mass","volume":"12","author":"Solloway","year":"2015","journal-title":"Cell Rep."},{"issue":"7871","key":"10.1016\/j.phrs.2025.108077_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(74)91343-9","article-title":"A glucagonoma syndrome","volume":"2","author":"Mallinson","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2025.108077_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.102024","article-title":"Dietary protein defends lean mass and maintains the metabolic benefits of glucagon receptor agonism in mice","volume":"89","author":"Lopes","year":"2024","journal-title":"Mol. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib94","article-title":"Hypoaminoacidemia underpins glucagon-mediated energy expenditure and weight loss","volume":"3","author":"Hope","year":"2022","journal-title":"Cell Rep. Med"},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib95","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0361-9230(85)90153-4","article-title":"Peptides and the blood-brain barrier: lipophilicity as a predictor of permeability","volume":"15","author":"Banks","year":"1985","journal-title":"Brain Res Bull."},{"issue":"14","key":"10.1016\/j.phrs.2025.108077_bib96","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1073\/pnas.81.14.4368","article-title":"Identification of glucagon receptors in rat brain","volume":"81","author":"Hoosein","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib97","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1507\/endocrj1954.27.Supplement_135","article-title":"Glucagon-like substance in the canine brain","volume":"27","author":"Sasaki","year":"1980","journal-title":"Endocrinol. Jpn"},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib98","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/db11-1556","article-title":"Direct control of brown adipose tissue thermogenesis by central nervous system glucagon-like peptide-1 receptor signaling","volume":"61","author":"Lockie","year":"2012","journal-title":"Diabetes"},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib99","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1210\/endo.134.5.8156917","article-title":"Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse","volume":"134","author":"Campos","year":"1994","journal-title":"Endocrinology"},{"issue":"1-2","key":"10.1016\/j.phrs.2025.108077_bib100","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0006-8993(93)90663-8","article-title":"Glucagon and the paraventricular hypothalamus: modulation of energy balance","volume":"630","author":"Atrens","year":"1993","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib101","article-title":"Glucagon receptor signaling regulates weight loss via central KLB receptor complexes","volume":"6","author":"Nason","year":"2021","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib102","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/db09-1878","article-title":"Fibroblast growth factor 21 action in the brain increases energy expenditure and insulin sensitivity in obese rats","volume":"59","author":"Sarruf","year":"2010","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib103","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1210\/en.2014-2001","article-title":"Central Fibroblast Growth Factor 21 Browns White Fat via Sympathetic Action in Male Mice","volume":"156","author":"Douris","year":"2015","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib104","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1002\/cne.24668","article-title":"The central fibroblast growth factor receptor\/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform","volume":"527","author":"Hultman","year":"2019","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.phrs.2025.108077_bib105","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101564","article-title":"Pharmacological FGF21 signals to glutamatergic neurons to enhance leptin action and lower body weight during obesity","volume":"64","author":"Claflin","year":"2022","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib106","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.cmet.2014.03.031","article-title":"Estradiol regulates brown adipose tissue thermogenesis via hypothalamic AMPK","volume":"20","author":"Martinez de Morentin","year":"2014","journal-title":"Cell Metab."},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib107","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s42255-021-00467-8","article-title":"Small extracellular vesicle-mediated targeting of hypothalamic AMPKalpha1 corrects obesity through BAT activation","volume":"3","author":"Milbank","year":"2021","journal-title":"Nat. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib108","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuron.2005.12.021","article-title":"Leptin directly activates SF1 neurons in the VMH, and this action by leptin is required for normal body-weight homeostasis","volume":"49","author":"Dhillon","year":"2006","journal-title":"Neuron"},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib109","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1016\/j.celrep.2017.05.066","article-title":"Thyroid hormone receptor beta in the ventromedial hypothalamus is essential for the physiological regulation of food intake and body weight","volume":"19","author":"Hameed","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.phrs.2025.108077_bib110","doi-asserted-by":"crossref","DOI":"10.1172\/JCI134135","article-title":"Ventromedial hypothalamic nucleus neuronal subset regulates blood glucose independently of insulin","author":"Flak","year":"2020","journal-title":"J. Clin. Invest"},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib111","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.cmet.2020.06.008","article-title":"FGF21 Signals to Glutamatergic Neurons in the Ventromedial Hypothalamus to Suppress Carbohydrate Intake","volume":"32","author":"Jensen-Cody","year":"2020","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib112","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/s41598-020-62468-z","article-title":"Paraventricular, subparaventricular and periventricular hypothalamic IRS4-expressing neurons are required for normal energy balance","volume":"10","author":"Sutton","year":"2020","journal-title":"Sci. Rep."},{"issue":"46","key":"10.1016\/j.phrs.2025.108077_bib113","doi-asserted-by":"crossref","first-page":"15306","DOI":"10.1523\/JNEUROSCI.0226-14.2014","article-title":"Control of food intake and energy expenditure by Nos1 neurons of the paraventricular hypothalamus","volume":"34","author":"Sutton","year":"2014","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib114","first-page":"E314","article-title":"Loss of glucagon suppression of feeding after vagotomy in rats","volume":"234","author":"Martin","year":"1978","journal-title":"Am. J. Physiol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib115","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/0031-9384(88)90220-X","article-title":"Lesion of vagal afferent terminals impairs glucagon-induced suppression of food intake","volume":"43","author":"Weatherford","year":"1988","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.phrs.2025.108077_bib116","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0021-9258(18)64236-X","article-title":"Effect of glucagon on the metabolism of adipose tissue","volume":"236","author":"Hagen","year":"1961","journal-title":"J. Biol. Chem."},{"issue":"1 Pt 2","key":"10.1016\/j.phrs.2025.108077_bib117","first-page":"R160","article-title":"Glucagon stimulation of brown adipose tissue growth and thermogenesis","volume":"252","author":"Billington","year":"1987","journal-title":"Am. J. Physiol."},{"issue":"2 Pt 2","key":"10.1016\/j.phrs.2025.108077_bib118","first-page":"R501","article-title":"Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo","volume":"261","author":"Billington","year":"1991","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2025.108077_bib119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.molmet.2019.01.011","article-title":"The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice","volume":"22","author":"Beaudry","year":"2019","journal-title":"Mol. Metab."},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3109\/07853890.2014.919727","article-title":"The brain and brown fat","volume":"47","author":"Contreras","year":"2015","journal-title":"Ann. Med"},{"key":"10.1016\/j.phrs.2025.108077_bib121","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fnsys.2015.00150","article-title":"Hypothalamic control of brown adipose tissue thermogenesis","volume":"9","author":"Labbe","year":"2015","journal-title":"Front Syst. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib122","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.cmet.2024.03.008","article-title":"Futile cycles: Emerging utility from apparent futility","volume":"36","author":"Sharma","year":"2024","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib123","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11154-021-09690-w","article-title":"ATP-consuming futile cycles as energy dissipating mechanisms to counteract obesity","volume":"23","author":"Brownstein","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib124","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s42255-024-01003-0","article-title":"Futile lipid cycling: from biochemistry to physiology","volume":"6","author":"Sharma","year":"2024","journal-title":"Nat. Metab."},{"issue":"6778","key":"10.1016\/j.phrs.2025.108077_bib125","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/35007527","article-title":"Towards a molecular understanding of adaptive thermogenesis","volume":"404","author":"Lowell","year":"2000","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib126","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0165-1838(95)00007-K","article-title":"Increased muscle sympathetic nerve activity after glucagon administration in man","volume":"54","author":"Takayama","year":"1995","journal-title":"J. Auton. Nerv. Syst."},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib127","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00702-004-0199-7","article-title":"Role of catecholamines in glucagon-induced thermogenesis","volume":"112","author":"Filali-Zegzouti","year":"2005","journal-title":"J. Neural Transm."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib128","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4093\/dmj.2023.0011","article-title":"Adipose Tissue and Metabolic Health","volume":"47","author":"An","year":"2023","journal-title":"Diabetes Metab. J."},{"issue":"27","key":"10.1016\/j.phrs.2025.108077_bib129","doi-asserted-by":"crossref","first-page":"5191","DOI":"10.1016\/j.febslet.2007.09.064","article-title":"FXR-deficiency confers increased susceptibility to torpor","volume":"581","author":"Cariou","year":"2007","journal-title":"FEBS Lett."},{"issue":"7075","key":"10.1016\/j.phrs.2025.108077_bib130","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature04330","article-title":"Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation","volume":"439","author":"Watanabe","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.108077_bib131","unstructured":"Montero A.S.G., Presiado M., Hamel L.K.F.F. Health Tracking Poll May 2024: The Public\u2019s Use and Views of GLP-1 Drugs. 2024."},{"key":"10.1016\/j.phrs.2025.108077_bib132","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2025.2499670","article-title":"Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system","author":"McCall","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2025.108077_bib133","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14740338.2024.2430306","article-title":"Increased reporting of accidental overdose with glucagon-like peptide-1 receptor agonists: a population-based study","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib134","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib135","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.721135","article-title":"GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib136","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6","key":"10.1016\/j.phrs.2025.108077_bib137","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.jhep.2023.07.033","article-title":"Incretins (GLP-1 receptor agonists and dual\/triple agonists) and the liver","volume":"79","author":"Newsome","year":"2023","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib138","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S2213-8587(23)00356-X","article-title":"Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial","volume":"12","author":"le Roux","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib139","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.2337\/db17-1502","article-title":"Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21","volume":"67","author":"Kim","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.phrs.2025.108077_bib140","unstructured":"Kim T., Pearson M.J., Hong H., Nason S., Seck K., Antipenko J., Presedo N., DiMarchi R., Roell W.C., Habegger K. Bile Acid Binding Resins Improve Glucagon Receptor Agonist-Mediated Weight Loss in Diet-Induced Obese Mice. Obesity;n\/a(n\/a)."},{"issue":"776","key":"10.1016\/j.phrs.2025.108077_bib141","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk4908","article-title":"Glp1r-Lepr coexpressing neurons modulate the suppression of food intake and body weight by a GLP-1\/leptin dual agonist","volume":"16","author":"Polex-Wolf","year":"2024","journal-title":"Sci. Transl. Med"},{"issue":"17","key":"10.1016\/j.phrs.2025.108077_bib142","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1111\/bph.15860","article-title":"A GLP-1\/glucagon (GCG)\/CCK(2) receptors tri-agonist provides new therapy for obesity and diabetes","volume":"179","author":"Zhao","year":"2022","journal-title":"Br. J. Pharm."},{"issue":"10403","key":"10.1016\/j.phrs.2025.108077_bib143","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Investigators O. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib144","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Investigators G. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med"},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib145","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13929","article-title":"Discontinuing glucagon-like peptide-1 receptor agonists and body habitus: A systematic review and meta-analysis","volume":"26","author":"Berg","year":"2025","journal-title":"Obes. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib146","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw. Open"},{"issue":"3","key":"10.1016\/j.phrs.2025.108077_bib147","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.phrs.2025.108077_bib148","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Group SS. Once-Weekly Semaglutide in Adults with Overweight or Obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib149","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1111\/dom.13353","article-title":"Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1\u20135 trials","volume":"20","author":"Ahren","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib150","doi-asserted-by":"crossref","DOI":"10.1007\/s11154-025-09963-8","article-title":"Weight cycling and its effects on muscle mass, sarcopenia and sarcopenic obesity","author":"Zamboni","year":"2025","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.phrs.2025.108077_bib151","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1749-6632.2000.tb06482.x","article-title":"Body fat content influences the body composition response to nutrition and exercise","volume":"904","author":"Forbes","year":"2000","journal-title":"Ann. N. Y Acad. Sci."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib152","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1111\/dom.15913","article-title":"Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps","volume":"26","author":"Dubin","year":"2024","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib153","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"issue":"14","key":"10.1016\/j.phrs.2025.108077_bib154","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib155","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib156","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/oby.22493","article-title":"Weight Cycling as a Risk Factor for Low Muscle Mass and Strength in a Population of Males and Females with Obesity","volume":"27","author":"Rossi","year":"2019","journal-title":"Obes. (Silver Spring)"},{"issue":"10","key":"10.1016\/j.phrs.2025.108077_bib157","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.2337\/dci23-0100","article-title":"Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?","volume":"47","author":"Locatelli","year":"2024","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib158","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/dom.15113","article-title":"Effect of the glucagon-like peptide-1 receptor agonist liraglutide, compared to caloric restriction, on appetite, dietary intake, body fat distribution and cardiometabolic biomarkers: A randomized trial in adults with obesity and prediabetes","volume":"25","author":"Silver","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2024.101880","article-title":"Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonism","volume":"80","author":"Nunn","year":"2024","journal-title":"Mol. Metab."},{"key":"10.1016\/j.phrs.2025.108077_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.07.525","article-title":"Development of a novel fusion protein, JUV-161, that enhances muscle regeneration for treatment of myotonic dystrophy type 1","volume":"43","author":"Kim","year":"2024","journal-title":"Neuromuscul. Disord."},{"issue":"17","key":"10.1016\/j.phrs.2025.108077_bib161","doi-asserted-by":"crossref","first-page":"6241","DOI":"10.3390\/ijms21176241","article-title":"Induction of Adipose Tissue Browning as a Strategy to Combat Obesity","volume":"21","author":"Kury\u0142owicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib162","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cardfail.2023.03.017","article-title":"Increased Risk of Heart Failure Hospitalization With GLP-1 Receptor Agonists in Patients With Reduced Ejection Fraction: A Meta-Analysis of the EXSCEL and FIGHT Trials","volume":"29","author":"Neves","year":"2023","journal-title":"J. Card. Fail"},{"issue":"4","key":"10.1016\/j.phrs.2025.108077_bib163","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1161\/CIRCHEARTFAILURE.114.000346","article-title":"Heart Failure Clinical Research N. GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study","volume":"7","author":"Margulies","year":"2014","journal-title":"Circ. Heart Fail"},{"issue":"8","key":"10.1016\/j.phrs.2025.108077_bib164","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/01.CIR.0000120505.91348.58","article-title":"Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion","volume":"109","author":"Nikolaidis","year":"2004","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib165","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.cardfail.2006.08.211","article-title":"Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure","volume":"12","author":"Sokos","year":"2006","journal-title":"J. Card. Fail"},{"issue":"2","key":"10.1016\/j.phrs.2025.108077_bib166","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.molmet.2014.11.005","article-title":"Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction","volume":"4","author":"Ali","year":"2015","journal-title":"Mol. Metab."},{"issue":"1","key":"10.1016\/j.phrs.2025.108077_bib167","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12933-019-0806-4","article-title":"Targeting the glucagon receptor improves cardiac function and enhances insulin sensitivity following a myocardial infarction","volume":"18","author":"Karwi","year":"2019","journal-title":"Cardiovasc Diabetol."},{"issue":"5","key":"10.1016\/j.phrs.2025.108077_bib168","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCRESAHA.124.324706","article-title":"Glucagon Receptor Antagonist for Heart Failure With Preserved Ejection Fraction","volume":"135","author":"Gao","year":"2024","journal-title":"Circ. Res"},{"key":"10.1016\/j.phrs.2025.108077_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101180","article-title":"GLP-1 improves the supportive ability of astrocytes to neurons by promoting aerobic glycolysis in Alzheimer's disease","volume":"47","author":"Zheng","year":"2021","journal-title":"Mol. Metab."},{"issue":"12","key":"10.1016\/j.phrs.2025.108077_bib170","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.phrs.2025.108077_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069010","article-title":"The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice","volume":"8","author":"Egecioglu","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.phrs.2025.108077_bib172","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/phar.4607","article-title":"Incretin hormone agonists: current and emerging pharmacotherapy for obesity management","volume":"44","author":"Alhomoud","year":"2024","journal-title":"Pharmacotherapy"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500502X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366182500502X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:58:07Z","timestamp":1768431487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366182500502X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":172,"alternative-id":["S104366182500502X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108077","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.108077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108077"}}